PDCD1LG2 and head and neck squamous cell carcinoma: Since PD-L2’s critical role in the immune escape process, amounts of small molecular drugs targeting transcription factors of PD-L2 serve as beneficial strategies with therapeutic potential and have already been used in the clinical treatment of both HNSCC and other solid tumours.